ARA-290 vs Sermorelin
ARA-290 and Sermorelin are both peptide compounds evaluated on Vial: ARA-290 is not FDA approved for human use with clinical-trial evidence, and Sermorelin is legally compoundable with clinical-trial evidence.
Vial summary · compiled from public records
At a glance
Sermorelin
- Category
- Peptide
- FDA / legal status
- Legally Compoundable
- Route
- Subcutaneous
Side by side
| Field | ARA-290 | Sermorelin |
|---|---|---|
| Category | Peptide | Peptide |
| Brand names | — | — |
| FDA / legal status | Gray Market | Legally Compoundable |
| Evidence tier | Clinical Trials | Clinical Trials |
| Administration route | — | Subcutaneous |
| Compounding access | Not FDA approved, limited regulated access | Legally Compoundable |
| Providers on Vial | 0 listed | 27 listed |
| Typical price band | Varies by provider | $$ to $$$ |
Verified providers offering each
Ranked by Vial Score, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
ARA-2900 top providers
No surfaceable providers currently list ARA-290 on Vial.
See all 0 providers offering ara-290 →About each compound
About ARA-290
ARA-290 is a synthetic 11-amino-acid peptide that selectively activates the innate repair receptor (a heterodimer of the EPO receptor and beta common receptor) without erythropoietic effects, providing neuroprotection, anti-inflammatory, and tissue-repair actions. It has completed Phase II trials for neuropathic pain in sarcoidosis and is being studied for small fiber neuropathy, diabetic neuropathy, and inflammatory conditions. It represents a novel approach to harnessing erythropoietin's tissue-protective properties without its blood-thickening risks.
About Sermorelin
A synthetic analog of growth hormone-releasing hormone (GHRH), this 29-amino acid peptide stimulates the pituitary gland to produce and secrete endogenous growth hormone through binding to GHRH receptors. It functions by mimicking the N-terminal bioactive portion of native GHRH, promoting pulsatile GH release while preserving the body's natural feedback mechanisms. Primary applications include diagnostic testing of pituitary function and therapeutic use in growth hormone deficiency.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.